Teva gives up on partner's inhaler; Noninvasive neurostimulator performs well in trial;

@FierceMedDev: 450+ hospitals pay DOJ $250M for overuse of ICDs at the expense of Medicare. Report | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Flowonix to develop drug delivery implant for Cerebral's neurological candidates. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI Friday: Quest Medical launches recall for open heart surgery drug delivery devices. Article | Follow @EmilyWFierce

> Alexza Pharmaceuticals ($ALXA) is reacquiring the U.S. rights to its adasuve inhalation powder from Teva ($TEVA). The company aims to find a new partner next year for the product to treat central nervous system conditions. It's delivered into the lungs via the Staccato hand-held inhaler. More

> Helius Medical Technologies announced that its Portable Neuromodulation Stimulator met its study objectives in a trial on multiple sclerosis patients. The noninvasive device delivers neurostimulation through the tongue. Helius says it plans on filing for FDA clearance of the device. More

Biotech News

@FierceBiotech: The top 10 biopharma pipeline disasters of 2015. Feature | Follow @FierceBiotech

@JohnCFierce: ICYMI: AstraZeneca's olaparib looks promising for a targeted set of prostate cancer patients. Story | Follow @JohnCFierce

@DamianFierce: Solid use of the double question mark in the otherwise disappointing Citron $VRX screed. More | Follow @DamianFierce

> Bristol-Myers bets $2B on Cardioxyl's heart failure therapy. Report

> Boehringer expands its crowdsourced research to include psychiatric R&D. Item

> Merck KGaA inks cancer metabolism drug discovery alliance with Selvita. Article

Pharma News

@FiercePharma: Novartis sees doc-education push, DTC as crucial to amping up Entresto launch. FiercePharmaMarketing story | Follow @FiercePharma

@EricPFierce: ICYMI: Pfizer and GlaxoSmithKline are collaborating on continuous manufacturing. FiercePharmaManufacturing item | Follow @EricPFierce

@CarlyHFierce: Shire locks down rivals to its rare-disease franchise with $5.9B Dyax buy. News | Follow @CarlyHFierce

> It's open season for Mylan's EpiPen as Sanofi, Teva stumble. Item

> FDA finds fault with Pfizer China plant. Story

> JAMA: 'Groundbreaking,' 'miracle' drugs not all they're cracked up to be in news stories. More

Animal Health News

> Investors cheer Abaxis but trounce IDEXX on quarterly diagnostics performance. More

> NexGard demand drives strong Q3 growth for Sanofi's Merial. Item

> Tufts vet borrows techniques from human medicine to repair facial fractures in dogs. Story

> Colorado State University scientists use fertility know-how to revive Yellowstone bison. Report

> VCA beats on earnings but misses the mark on revenue in Q3. Article

Biotech IT News

> Ex-BGI CEO sets up AI-enabled health data mining operation. Report

> Genomics boom puts strain on data storage, electricity grid. Story

> Alibaba, BGI and Intel team up for precision medicine project. Article

> Chinese sequencing sector heats up as BGI, Direct Genomics prepare products. Item

> FDA seeks industry feedback on virtual and BYOD clinical trials. More

Pharma Marketing News

> Shire dodges HAE competition with $5.9B Dyax buyout. Item

> Sanofi's Auvi-Q recall puts Mylan's rival EpiPen in full control of blockbuster market. Report

> Novartis sees doc-education push, DTC as crucial to amping up Entresto launch. Story

> Feds arrest, charge ex-Warner Chilcott sales execs in kickbacks case. More

> GSK readies respiratory sales force to challenge Xolair in severe asthma. Article

Suggested Articles

Abbott launched a rapid coronavirus test able to deliver positive results in as little as five minutes from a tabletop box the size of a toaster.

The FDA will be working with government and public-private partners to distribute and evaluate 3D designs and models.

The FDA issued a wide-ranging emergency policy allowing alternative devices to be used as potentially lifesaving ventilators amid new shortages.